DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Amgen 

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display





 Company News
Amgen (AMGN) To Host Summary Webcast Of Kyprolis® (Carfilzomib) For Injection Data Presented At The European Society For Medical Oncology (ESMO) 2014 Congress 9/25/2014 7:55:23 AM
Amgen (AMGN) Asks FDA For Biologics License For Breakthrough Cancer Drug Blinatumomab 9/22/2014 8:14:27 AM
Amgen (AMGN) Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis 9/16/2014 7:30:28 AM
Amgen (AMGN) Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9/15/2014 7:09:35 AM
Amgen (AMGN) Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9/10/2014 9:29:31 AM
Amgen (AMGN) To Present At The Morgan Stanley Global Healthcare Conference 9/8/2014 8:21:43 AM
Amgen (AMGN), Servier Heart Drug Runs Into Safety Concerns In Major Clinical Study 9/3/2014 6:31:01 AM
Amgen (AMGN) Submits Marketing Authorization Application For Talimogene Laherparepvec 9/2/2014 7:22:33 AM
Amgen (AMGN) Submits Marketing Authorization Application For Cholesterol-Lowering Medication Evolocumab 9/2/2014 6:57:24 AM
Amgen (AMGN) Submits BLA For Cholesterol Drug Evolocumab 8/28/2014 9:03:05 AM
12345678910...